CRPM
A neo-epitope fragment of C-reactive protein generated by matrix metalloproteinase activity, enabling non-invasive monitoring of local tissue inflammation and disease activity in chronic joint disorders.
Key features and values
- Detects a specific neo-epitope of CRP produced by matrix metalloproteinase activity.
- Provides a non-invasive measure for assessing local tissue inflammation.
- Applicable in research on osteoarthritis, rheumatoid arthritis, and other inflammatory joint diseases.
- Facilitates monitoring of disease activity and therapeutic response.
- Supports evaluation of interventions aimed at modulating inflammatory processes.
- Complements other biomarkers for a comprehensive assessment of joint inflammation.
- Validated for use in research settings to advance understanding of inflammation-related pathology.
Description
The CRPM biomarker assay quantifies a specific neo-epitope fragment of C-reactive protein (CRP) generated by matrix metalloproteinase activity. This non-invasive assay serves as an indicator of local tissue inflammation, providing insights into disease activity in chronic joint disorders such as osteoarthritis and rheumatoid arthritis. By measuring CRPM levels, researchers can monitor disease progression, evaluate therapeutic efficacy, and stratify patients in clinical studies targeting inflammatory pathways. The assay supports a comprehensive understanding of inflammation-related pathology and its role in joint diseases.
Nordic Bioscience’s assays and services are research use only products and services and do not qualify for medical or diagnostic purposes.
